
Fapon Biopharma and MOTE Therapeutics Unveil B-Cell Immunotherapy Suite
At the BIO 2026 International Convention in San Diego, Fapon Group subsidiaries Fapon Biopharma and MOTE Therapeutics are debuting a dual-platform strategy designed to tackle autoimmune diseases. The companies intend to leverage combined T-cell engager and in vivo CAR-T technologies to achieve durable B-cell depletion in upcoming clinical trials.























